Navigation Links
GW Pharmaceuticals plc Reports 2013 Q4 and Full Year Financial Results
Date:11/19/2013

2,900820Trade and other receivables

9

2,8041,7331,588Cash and cash equivalents61,58838,06929,33578,07248,25835,280Total assets95,36058,94442,922Current liabilitiesTrade and other payables

10

(15,272)(9,440)(9,114)Obligations under finance leases

12

(162)(100)–Deferred revenue

11

(5,146)(3,181)(2,449)(20,580)(12,721)(11,563)Non-current liabilitiesObligations under finance leases

12

(3,082)(1,905)–Deferred revenue

11

(14,424)(8,916)(10,127)Total liabilities(17,506)(23,542)(21,690)Net assets57,27435,40221,232EquityShare capital

13

288178133Share premium account135,90384,00565,947Other reserves32,65420,18420,184Retained earnings (111,571)(68,965)(65,032)Shareholders' funds57,27435,40221,232This announcement was approved by the Board of Directors on 18 November 2013.GW Pharmaceuticals plc

Consolidated cash flow statement

For the year ended 30 September 2013Year endedYear endedYear ended30 September30 September30 September201320132012$000's£000's£000's(Loss)/profit for the year(7,359)(4,549)2,490Adjustments for:Interest expense

104641Interest income

(288)(178)(200)Tax

(9,395)(5,807)(1,248)Depreciation of property, plant and equipment

1,600989754Net foreign exchange (gains) / losses

(40)(25)(202)(Decrease)/increase in allowance for doubtful debts

(42)(26)26Decrease in inventory provision

(857)(530)(1,300)Share-based payment charge

9976161,009(15,280)(9,446)1,330Increase in inventories

(961)(594)(813)(Increase) / decrease in trade receivables and other assets

(175)(108)609(Decrease) / increase in trade and other payables and deferred revenue

(246)(152)247Cash (used in)/generated by operations(16,662)(10,300)1,373Research and development tax credits received

4,5822,832428Net cash (outflow)/inflow from operatin
'/>"/>

SOURCE GW Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)...  Encision Inc. (OTCQB:ECIA), a medical device company owning ... in minimally invasive surgery, today announced financial results for ... The Company posted quarterly net revenue of ... thousand, or $(0.02) per share. These results compare to ... of $311 thousand, or $(0.04) per share, in the ...
(Date:7/29/2014)... , July 29, 2014   ... announced that it has taken an exclusive worldwide licence ... Ltd, a Durham University spin-out ... will pay an upfront fee, development and commercial milestone ... has also taken an option for additional exclusive licences ...
(Date:7/28/2014)... July 28, 2014  Dignity Health St. Mary,s ... the Get With The Guidelines®-Stroke Silver-Plus Quality Achievement ... by the American Heart Association/American Stroke Association for ... number four cause of death and a leading ... United States , according to the American ...
Breaking Medicine Technology:Encision Reports First Quarter Fiscal Year 2015 Results 2Encision Reports First Quarter Fiscal Year 2015 Results 3Encision Reports First Quarter Fiscal Year 2015 Results 4Glide Pharma Takes Exclusive Worldwide Rights to Novel Diagnostic Technology for Prostate Cancer 2Glide Pharma Takes Exclusive Worldwide Rights to Novel Diagnostic Technology for Prostate Cancer 3Dignity Health St. Mary's Medical Center Honored with Quality Achievement Award for Stroke Care 2Dignity Health St. Mary's Medical Center Honored with Quality Achievement Award for Stroke Care 3
... published in the American Journal of Nephrology -, ... announced that its Phase III data on VAPRISOL was ... Nephrology. In this study,VAPRISOL showed a significant increase in ... life-threatening condition that,occurs when the body,s sodium level falls ...
... Cancer patients at Beaumont,Hospitals are the first in the ... therapy that is painless, faster, more accurate and precise,than ... patented the new,technology, Omnibeam(R). The $3.3-million machine is manufactured ... first patient,was treated on Sept. 10. The painless ...
Cached Medicine Technology:Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia 2Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia 3Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia 4Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia 5Beaumont Patients 1st to get Next Generation of Radiation Treatment 2
(Date:7/29/2014)... Regents Health Resources, a consulting firm ... health care industry veteran Daryl Demonbreun and former St. ... the company’s ambitious plans to grow into a full-service ... moving along at a steady pace for nearly 20 ... notch,” says Bob Maier, founder and chief executive officer ...
(Date:7/29/2014)... Intermedix Corporation is proud to announce the ... The Clinical Data eXchange, or CDX, is an information ... data. , With this solution, state public health agencies, ... NEMSIS 3.0 compliant data from multiple field EMS data ... analyzed, and reported to the national NEMSIS data registry. ...
(Date:7/29/2014)... There is controversy over how best to treat ... Does one wait until the cancer comes back or ... recurrence? Now, a new study from Thomas ... help doctors and patients make a more informed decision. ... same," says first author Robert Den, M.D., Assistant Professor ...
(Date:7/29/2014)... procedure may enable more widespread use of preoperative testing ... with severe sleep apnea, suggests a study in ... and Dr. Jeff E. Mandel of the University of ... control" anesthetic technique for putting patients to sleep briefly-just ... apnea. The simplified technique requires no special expertise and ...
(Date:7/29/2014)... people can handle stressful situations better than others, ... identical twins show differences in how they respond. ... in the brains of genetically identical mice that ... stressful situations. , The findings, published July ... help researchers prevent potential consequences of chronic stress ...
Breaking Medicine News(10 mins):Health News:Sferrella and Demonbruen Join Regents Health Resources 2Health News:Intermedix Releases NEMSIS Compliant EMS Information System 2Health News:Genomic analysis of prostate cancer indicates best course of action after surgery 2Health News:New anesthesia technique helps show cause of obstruction in sleep apnea 2Health News:New anesthesia technique helps show cause of obstruction in sleep apnea 3Health News:A new brain-based marker of stress susceptibility 2
... each developed by Merck and Smith Glaxo Kline has found ... caused by the human papilloma viruses (HPVs). ... reduced infection in about 90% of the subjects. ... immunologic technologies have contributed to the discovery of the link ...
... revealed that having several older brothers increases the chances of ... //weight to the idea of a biological basis for sexual ... in St Catharines, Canada said, "It's likely to be a ... probably a biological basis for homosexuality." ,S Marc ...
... Graham Burton, M.D., SVP, Regulatory Affairs and Pharmacovigilance ... a new oral drug option// to the group ... ,Celgene Corporation (Nasdaq: CELG) announced that the U.S. ... for its Supplemental New Drug Application (sNDA) for ...
... had stated on Friday that the precedent conditions of ... outbreak at Durban's Mahatma Gandhi Memorial Hospital, which had ... Mseleku said, “Nobody needs to communicate these problems. We ... It's (overcrowding and staff shortages) a known fact.” That ...
... by K M Shah Dental College an eye wash and ... admission //process by with a supposed entrance test held by ... for granting admissions. ,The court, had issued a ... admission should continue and has asked the Gujarat University (GU) ...
... Quebec say that chronic job stress can raise blood ... ,The research, appearing in the American Journal of ... deadlines increased blood pressure especially in men. The study ... study supports the hypothesis that job strain, particularly in ...
Cached Medicine News:Health News:Klebsiella Outbreak In Durban Blamed On Staff Shortage & Overcrowding 2Health News:Gujarat High Court Stays PG Admissions In A Private Dental Collage 2
... Aplicare's saturated swabsticks are packaged in ... 4 inch swabstick is saturated with precisely ... The Gel Swabstick is saturated with a ... The gel is also approved for venipuncture ...
... BETADINE® Spray provides 5% ... pump spray. It delivers ... wounds too tender to ... and is indicated whenever ...
... that does not contain Alcohol. ... destroys over 99% of bacteria. ... of minor wounds, burns, cuts, ... personal utensils and tools. Prevents ...
BETADINE® Surgical Scrub is a microbicidal, sudsing cleanser that promptly kills most bacteria, fungi, viruses, protozoa and yeasts. It is indicated for hand hygiene, surgical hand-scrubbing, an...
Medicine Products: